Literature DB >> 31960558

Use of pre-ART laboratory screening to identify renal, hepatic and haematological abnormalities in Côte d'Ivoire.

P A Minchella1, C Adjé-Touré2, G Zhang1, A Tehe2, J Hedje2, E R Rottinghaus1, K Natacha2, K Diallo3, G L Ouedraogo2, J N Nkengasong4.   

Abstract

BACKGROUND: High demand for HIV-services and extensive clinical guidelines force health systems in low-resource settings to dedicate resources to service delivery at the expense of other priorities. Simplifying services may reduce the burden on health systems and pre-antiretroviral therapy (ART) laboratory screening is among the services under consideration for simplification.
METHODS: We assessed the frequencies of conditions linked to ART toxicities among 34,994 adult, ART-naïve patients with specimens referred to the RETRO-CI laboratory in Abidjan, Côte d'Ivoire between 1998 and 2017. Screening included tests for serum creatinine, alanine aminotransferase (ALT) and haemoglobin (Hb) to identify renal dysfunction (estimated glomerular filtration rate < 50 mL/min), hepatic abnormalities (ALT > 5× upper limit of normal) and severe anaemia (Hb < 6.5 g/dL), respectively. We considered screening results across four eras and identified factors associated with the conditions in question.
RESULTS: The prevalence of renal dysfunction, hepatic abnormalities and severe anaemia were largely unchanged over time and just 8.4% of patients had any of the three conditions. Key factors associated with renal dysfunction and severe anaemia were age > 50 years (adjusted odds ratio (aOR): 2.53; 95% confidence interval (CI): 2.19-2.92; P < 0.001) and CD4 < 100 cells/µl (aOR: 2.57; 95% CI: 2.30-2.88; P < 0.001).
CONCLUSION: The relative infrequency of conditions linked to toxicity in Côte d'Ivoire supports the notion that simplification of pre-ART laboratory screening may be undertaken with limited negative impact on identification of adverse events. Targeted screening may be a feasible strategy to balance detection of conditions associated with ART toxicities with simplification of services. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Côte d'Ivoire; Côte d’Ivoire; HIV; VIH; anaemia; anémie; toxicity; toxicité

Mesh:

Substances:

Year:  2020        PMID: 31960558      PMCID: PMC8450936          DOI: 10.1111/tmi.13364

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   3.918


  21 in total

1.  Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.

Authors:  Christopher J Hoffmann; Katherine L Fielding; Salome Charalambous; Mark S Sulkowski; Craig Innes; Chloe L Thio; Richard E Chaisson; Gavin J Churchyard; Alison D Grant
Journal:  AIDS       Date:  2008-01-02       Impact factor: 4.177

2.  Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized Clinical Trial.

Authors:  Niklaus D Labhardt; Isaac Ringera; Thabo I Lejone; Thomas Klimkait; Josephine Muhairwe; Alain Amstutz; Tracy R Glass
Journal:  JAMA       Date:  2018-03-20       Impact factor: 56.272

3.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.

Authors:  Jeffrey S A Stringer; Isaac Zulu; Jens Levy; Elizabeth M Stringer; Albert Mwango; Benjamin H Chi; Vilepe Mtonga; Stewart Reid; Ronald A Cantrell; Marc Bulterys; Michael S Saag; Richard G Marlink; Alwyn Mwinga; Tedd V Ellerbrock; Moses Sinkala
Journal:  JAMA       Date:  2006-08-16       Impact factor: 56.272

Review 4.  Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.

Authors:  Andrew M Hall; Bruce M Hendry; Dorothea Nitsch; John O Connolly
Journal:  Am J Kidney Dis       Date:  2011-03-23       Impact factor: 8.860

5.  Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings.

Authors:  Agnes N Kiragga; Barbara Castelnuovo; Damalie Nakanjako; Yukari C Manabe
Journal:  J Int AIDS Soc       Date:  2010-11-03       Impact factor: 5.396

6.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

7.  Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial.

Authors:  Sydney Rosen; Mhairi Maskew; Matthew P Fox; Cynthia Nyoni; Constance Mongwenyana; Given Malete; Ian Sanne; Dorah Bokaba; Celeste Sauls; Julia Rohr; Lawrence Long
Journal:  PLoS Med       Date:  2016-05-10       Impact factor: 11.069

8.  Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial.

Authors:  Willem D F Venter; Mohammed Majam; Godspower Akpomiemie; Natasha Arulappan; Michelle Moorhouse; Nonkululeko Mashabane; Matthew F Chersich
Journal:  BMC Public Health       Date:  2017-07-04       Impact factor: 3.295

9.  Prevalence of anemia before and after initiation of antiretroviral therapy among HIV infected patients at Black Lion Specialized Hospital, Addis Ababa, Ethiopia: a cross sectional study.

Authors:  Gashaw Garedew Woldeamanuel; Diresibachew Haile Wondimu
Journal:  BMC Hematol       Date:  2018-03-15

10.  Assessment of GFR by four methods in adults in Ashanti, Ghana: the need for an eGFR equation for lean African populations.

Authors:  John B Eastwood; Sally M Kerry; Jacob Plange-Rhule; Frank B Micah; Sampson Antwi; Frances G Boa; Debasish Banerjee; Lynsey Emmett; Michelle A Miller; Francesco P Cappuccio
Journal:  Nephrol Dial Transplant       Date:  2010-01-25       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.